View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Aegon reports second half year 2025 results

Aegon reports second half year 2025 results Schiphol, February 19, 2026 - Please click  to access all 2H 2025 results related documents  2H 2025 Financial highlights Net result of EUR 375 million, a decrease compared with EUR 741 million in the second half of 2024, as growth in the operating result is offset by non-operating items and other charges. Full-year 2025 net result of EUR 980 million, up 45% compared with 2024 Operating result of EUR 858 million, up 11% compared with the second half of 2024 driven by an increase across all business units, reflecting commercial momentum and favor...

 PRESS RELEASE

argenx to Report Full Year 2025 Financial Results and Fourth Quarter B...

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 February 19, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of th...

 PRESS RELEASE

Participation notifications by The Goldman Sachs Group

Participation notifications by The Goldman Sachs Group Press release                                                                  Regulated information  Brussels, February 17, 2026, 17:45 CET  In line with Belgian transparency legislation (Law of May 2, 2007), The Goldman Sachs Group, Inc recently sent to Solvay the following transparency notifications. Here is a summary of the notifications:  Date on which the threshold is crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalFebruary 6, 20260.23%7.59%7.83%February 11, 20260.28%7.34%7.62...

 PRESS RELEASE

Notifications de participation par The Goldman Sachs Group

Notifications de participation par The Goldman Sachs Group Communiqué de presse                                                                 Information réglementée   Bruxelles, le 17 février 2026 - 17h45 CET  Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), The Goldman Sachs Group, Inc a envoyé récemment à Solvay les notifications de transparence suivantes. Voici un résumé des notifications:  Date de dépassement de seuil Droits de vote Instruments financiers équivalents Total 6 février 2026 ...

 PRESS RELEASE

Participatiemeldingen van The Goldman Sachs Group

Participatiemeldingen van The Goldman Sachs Group Persbericht                                                                 Gereglementeerde informatie  Brussel, 17 februari 2026 - 17u45 CET  In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft The Goldman Sachs Group, Inc onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd. Hier is een samenvatting van de bewegingen:  Datum waarop de drempel werd overschreden Stemrechten Aan stemrechten gelijkgestelde financiële instrumenten Totaal 6 februari 2026 ...

Mathijs Geerts Danau
  • Mathijs Geerts Danau

Inventiva FIRST LOOK: preliminary FY25 results hold no surprises

Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.

Guy Sips ... (+3)
  • Guy Sips
  • Mathijs Geerts Danau
  • Wim Hoste
 PRESS RELEASE

Inventiva reports preliminary 2025¹ fiscal year financial results

Inventiva reports preliminary 2025¹ fiscal year financial results Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the developmen...

 PRESS RELEASE

Inventiva publie ses résultats financiers préliminaires pour l’exercic...

Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹ Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 2025Réalisation d’une offre au public aux États-Unis pour un produit brut total d’environ 172,5 millions de dollars (149 millions d’euros)3Horizon de trésorerie prévue jusqu’au milieu du premier trimestre 20274 Daix (France), New York City (New York, Etats-Unis), le 17 février 2026 – (Euronext Paris and Nasdaq :IVA) (« Inventiva » ou ...

Stefano Toffano
  • Stefano Toffano
 PRESS RELEASE

Participation notifications by The Goldman Sachs Group

Participation notifications by The Goldman Sachs Group Press release                                                                  Regulated information  Brussels, February 12, 2026, 17:45 CET  In line with Belgian transparency legislation (Law of May 2, 2007), The Goldman Sachs Group, Inc recently sent to Solvay the following transparency notifications. The Goldman Sachs Group, Inc was already above the 5% threshold since June 2025, with a total of 5.54%, of which 5.51% equivalent financial instruments.  Here is a summary of the notifications:  Date on which the threshold is crossed V...

 PRESS RELEASE

Notifications de participation par The Goldman Sachs Group

Notifications de participation par The Goldman Sachs Group Communiqué de presse                                                                 Information réglementée   Bruxelles, le 12 février 2026 - 17h45 CET  Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), The Goldman Sachs Group, Inc a envoyé récemment à Solvay les notifications de transparence suivantes. The Goldman Sachs Group, Inc était déjà au-dessus du seuil de 5% depuis juin 2025, avec un total de 5,54%, dont 5,51% en instruments financiers équivalents. Voici...

 PRESS RELEASE

Participatiemeldingen van The Goldman Sachs Group

Participatiemeldingen van The Goldman Sachs Group Persbericht                                                                 Gereglementeerde informatie  Brussel, 12 februari 2026 - 17u45 CET  In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft The Goldman Sachs Group, Inc onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd. The Goldman Sachs Group, Inc had de drempel van 5% al overschreden in juni 2025 met een totaal van 5,54%, waarvan 5,51% aan stemrechten gelijkgestelde financiële instrumenten. Hier is een samenvatting van...

Guy Sips ... (+10)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...

 PRESS RELEASE

Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summi...

Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Daix (France), New York (United States), February 4, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New Yor...

 PRESS RELEASE

Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2...

Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026  Daix (France), New York (États-Unis), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à participer à un « fireside chat » lors du prochain Guggenheim Emerging Outlook: Biotech Summit 2026. La conférence se tiendra le...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen

Guy Sips ... (+5)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Wim Hoste
  • Wim Lewi
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch